Abstract
Is Allogeneic Hematopoietic Cell Transplantation Still an Option for Chronic Lymphocytic Leukemia in the Era of BTK Inhibition?
Highlights
Is Allogeneic Hematopoietic Cell Transplantation Still an Option for Chronic Lymphocytic Leukemia in the Era of Bruton’s tyrosine kinase (BTK) Inhibition?
Despite the high initial response rates reported with conventional chemo-immunotherapy [1,2], patients invariably relapse and may subsequently develop resistance to further conventional therapy.there is no evidence to date that conventional therapy is curative.Allogeneic hematopoietic cell transplantation (HCT) has been evaluatedas a treatment option to improve prognosis, in patients with poor-risk features or in those withrefractory disease [3,4,5,6,7,8,9]
Allogeneic HCT can be curative in the treatment of Chronic lymphocytic leukemia (CLL) due to the allo-immune graft-versus-leukemia effect [10,11,12]
Summary
Is Allogeneic Hematopoietic Cell Transplantation Still an Option for Chronic Lymphocytic Leukemia in the Era of BTK Inhibition?. Despite the high initial response rates reported with conventional chemo-immunotherapy [1,2], patients invariably relapse and may subsequently develop resistance to further conventional therapy.there is no evidence to date that conventional therapy is curative.Allogeneic hematopoietic cell transplantation (HCT) has been evaluatedas a treatment option to improve prognosis, in patients with poor-risk features or in those withrefractory disease [3,4,5,6,7,8,9].
Sign-in/Register to view highlights & summary 
Published Version
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a call